Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced dates for its R&D and Business Briefing and fourth-quarter 2011 sales and earnings report.

R&D and Business Briefing Details

Merck will hold its R&D and Business Briefing at 8:30 a.m. EST on Thursday, Nov. 10 at its corporate headquarters in Whitehouse Station, NJ. During the event, members of Merck's senior management will detail the company's research strategy, showcase candidates from the R&D pipeline and provide an update of business progress.

There will be a live audio webcast of the event on Merck's website at Software needed to listen to the webcast is available on the corporate website and should be downloaded prior to the beginning of the webcast. A replay of the R&D and Business Briefing webcast will be available by the end of the day and will remain on the website for 12 months.

Fourth-Quarter 2011 Sales and Earnings Conference Call Details

Merck plans to hold its fourth-quarter 2011 sales and earnings conference call with institutional investors and analysts at 8 a.m. EST on Thursday, Feb. 2. During the call the company will provide an overview of Merck's financial performance for the quarter. Information about accessing the conference call will be provided at a later date.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook and YouTube.


Ian McConnell, 908-423-3046
Carol Ferguson, 908-423-4465

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance



Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.